NASDAQ:NYXH Nyxoah (NYXH) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free NYXH Stock Alerts $9.41 +0.24 (+2.62%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$9.20▼$9.4650-Day Range$8.23▼$14.7252-Week Range$4.00▼$20.00Volume36,710 shsAverage Volume61,758 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$19.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Nyxoah alerts: Email Address Nyxoah MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside106.2% Upside$19.40 Price TargetShort InterestHealthy0.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.69) to ($1.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 stars 4.4 Analyst's Opinion Consensus RatingNyxoah has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNyxoah has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nyxoah's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.63% of the float of Nyxoah has been sold short.Short Interest Ratio / Days to CoverNyxoah has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nyxoah has recently decreased by 77.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNyxoah does not currently pay a dividend.Dividend GrowthNyxoah does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NYXH. Previous Next 2.0 News and Social Media Coverage News SentimentNyxoah has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nyxoah this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Nyxoah to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nyxoah insiders have not sold or bought any company stock.Percentage Held by Insiders17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Nyxoah's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nyxoah are expected to decrease in the coming year, from ($1.69) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nyxoah is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nyxoah is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNyxoah has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nyxoah's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsLEAKED: Jeff Bezos' $330 Million GambleDid you know that 3 simple words are disrupting a $62.7 billion market? "Blood Brain Barrier" Seems innocent enough.Here's how you could invest alongside them >>> About Nyxoah Stock (NASDAQ:NYXH)Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Read More NYXH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NYXH Stock News HeadlinesJune 1 at 3:42 AM | americanbankingnews.comNyxoah S.A. (NASDAQ:NYXH) Receives Average Rating of "Moderate Buy" from AnalystsMay 31 at 2:00 AM | globenewswire.comNyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional SharesMay 26, 2024 | uk.investing.comNyxoah shares target cut by H.C. Wainwright on capital raise dilutionMay 26, 2024 | americanbankingnews.comNyxoah (NASDAQ:NYXH) PT Lowered to $18.00May 23, 2024 | marketwatch.comNyxoah Shares Drop 15% After Public Offering LaunchesMay 23, 2024 | globenewswire.comNyxoah Announces Pricing of OfferingMay 22, 2024 | globenewswire.comNyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering ProgramMay 22, 2024 | globenewswire.comNyxoah Announces Proposed Offering of Ordinary SharesMay 17, 2024 | uk.investing.comNyxoah stock price target cut, maintains Overweight on Q1 revenue reportMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amidst Soaring Genio System Sales and Strategic PartnershipsMay 15, 2024 | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Buy Rating on Nyxoah (NYXH)May 14, 2024 | investorplace.comNYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q1 2024May 14, 2024 | finance.yahoo.comNyxoah Reports First Quarter 2024 Financial and Operating ResultsMay 13, 2024 | globenewswire.comNyxoah to Release First Quarter 2024 Financial Results on May 14, 2024May 10, 2024 | finance.yahoo.comInvitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024May 10, 2024 | globenewswire.comInvitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024April 11, 2024 | markets.businessinsider.comNyxoah Appoints Maurits Boon As Chief Medical OfficerApril 11, 2024 | globenewswire.comNyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical OfficerApril 11, 2024 | benzinga.comWhy Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | finance.yahoo.comInformation on the total number of voting rights and sharesMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture PotentialMarch 25, 2024 | globenewswire.comNyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth ProjectionsMarch 19, 2024 | msn.comNyxoah says Genio pivotal study meets primary endpointsMarch 19, 2024 | globenewswire.comNyxoah Announces DREAM U.S. Pivotal Study Meets Primary EndpointsSee More Headlines Receive NYXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today6/01/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NYXH CUSIPN/A CIK1857190 Webwww.nyxoah.com Phone321-022-2355Fax321-045-9075Employees146Year FoundedN/APrice Target and Rating Average Stock Price Target$19.40 High Stock Price Target$27.00 Low Stock Price Target$15.00 Potential Upside/Downside+106.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,770,000.00 Net Margins-843.49% Pretax Margin-873.66% Return on Equity-42.14% Return on Assets-33.55% Debt Debt-to-Equity Ratio0.13 Current Ratio3.94 Quick Ratio3.70 Sales & Book Value Annual Sales$4.70 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.08 per share Price / Book1.85Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.58 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Robert Taub MBA (Age 77)Co-Founder & Chairman Comp: $136.14kMr. Olivier Taelman (Age 52)CEO & Executive Director Comp: $673.23kMr. Loic Moreau (Age 43)Chief Financial Officer Comp: $338.16kMr. Bruno OnkelinxChief Technology OfficerMikaela KirkwoodCorporate Communication & Investor Relations ManagerMs. An MoonenGeneral CounselMr. Remi RenardVice President of Market & Market AccessMs. Inge VanwittenberghGlobal Human Resource DirectorMr. David M. DeMartinoChief Strategy OfficerMr. Jeyakumar SubbaroyanChief Clinical OfficerMore ExecutivesKey CompetitorsStevanato GroupNYSE:STVNLivaNovaNASDAQ:LIVNStrykerNYSE:SYKBoston ScientificNYSE:BSXBecton, Dickinson and CompanyNYSE:BDXView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Sold 24,800 shares on 5/29/2024Ownership: 0.000%Ikarian Capital LLCBought 50,699 shares on 5/17/2024Ownership: 0.000%Iron Triangle Partners LPBought 253,025 shares on 5/16/2024Ownership: 0.000%View All Institutional Transactions NYXH Stock Analysis - Frequently Asked Questions Should I buy or sell Nyxoah stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NYXH shares. View NYXH analyst ratings or view top-rated stocks. What is Nyxoah's stock price target for 2024? 6 Wall Street analysts have issued twelve-month target prices for Nyxoah's stock. Their NYXH share price targets range from $15.00 to $27.00. On average, they predict the company's stock price to reach $19.40 in the next year. This suggests a possible upside of 106.2% from the stock's current price. View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts. How have NYXH shares performed in 2024? Nyxoah's stock was trading at $4.64 at the beginning of 2024. Since then, NYXH stock has increased by 102.8% and is now trading at $9.41. View the best growth stocks for 2024 here. Are investors shorting Nyxoah? Nyxoah saw a decline in short interest in May. As of May 15th, there was short interest totaling 59,800 shares, a decline of 77.3% from the April 30th total of 263,200 shares. Based on an average trading volume of 47,200 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.6% of the company's stock are sold short. View Nyxoah's Short Interest. When is Nyxoah's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our NYXH earnings forecast. How were Nyxoah's earnings last quarter? Nyxoah S.A. (NASDAQ:NYXH) announced its earnings results on Tuesday, March, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The firm earned $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. Nyxoah had a negative net margin of 843.49% and a negative trailing twelve-month return on equity of 42.14%. When did Nyxoah IPO? Nyxoah (NYXH) raised $83 million in an initial public offering (IPO) on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share. Who are Nyxoah's major shareholders? Nyxoah's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (0.00%), Iron Triangle Partners LP (0.00%) and Ikarian Capital LLC (0.00%). How do I buy shares of Nyxoah? Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NYXH) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
